Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Latest Sheba Research Discovered Possible Treatment for ALS

The latest major breakthrough in ALS research and treatment could ultimately help slow down and even reverse the disease.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a degenerative muscle condition that impacts nerves in both the brain and spinal cord. ALS affects tens of thousands of people worldwide and has a mean survival rate of two to five years. As of yet, there has been no known cause or cure for the disease, which typically begins with muscle weakness or slurring and gradually progresses.

Recently, Dr. Amir Dori, Director of Sheba’s Neuromuscular Diseases Clinic, joined a team from Tel Aviv University, as well as scientists from Europe and the U.S., to conduct unique research on the root cause of ALS.

In a breakthrough discovery, the researchers found that ALS is caused by a buildup of a protein called TDP-43 in neuromuscular junctions responsible for translating signals from the brain to physical movements.

Beyond this notable initial finding, the team was also able to reduce that protein buildup through the use of a molecule originally developed to enhance neural regeneration after injury, offering a way to slow down the disease and potentially even reverse its debilitating effects.

This, the team believes, could eventually make ALS a treatable disease. Details of the research were documented in the journal Nature Communications


Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More